<table cellpadding="0pt" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="17%"></col>
<col width="83%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">CYP3A4 Substrates</content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Pimozide</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>Increased pimozide exposure</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>aprepitant is contraindicated [see <content stylecode="bold">CONTRAINDICATIONS (<linkhtml href="#i4i_contraindications_id_0173413b-91b5-4c16-960f-85fe369909d5">4</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Benzodiazepines</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical  Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="underline">125-mg/80-mg/80-mg aprepitant regimen</content>
</item>
</list>
<paragraph> • Monitor for benzodiazepine-related adverse reactions.</paragraph>
<list listtype="unordered">
<item>
<caption> </caption>• Depending on the clinical situation (e.g., elderly patients) and degree of monitoring available, reduce the dose of intravenous midazolam</item>
<item>
<caption> </caption>
<content stylecode="underline">Single 40 mg dose of aprepitant</content>
</item>
<item>
<caption> </caption>• No dosage adjustment of the benzodiazepine needed</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Dexamethasone</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>Increased dexamethasone exposure [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="underline">125-mg/80-mg/80-mg aprepitant regimen</content>
</item>
<item>
<caption> </caption>• Reduce the dose of oral dexamethasone by approximately 50% [see <content stylecode="bold">DOSAGE AND ADMINISTRATION (<linkhtml href="#_Ref">2.1</linkhtml>)</content>].</item>
<item>
<caption> </caption>
<content stylecode="underline">Single 40 mg dose of aprepitant</content>
</item>
<item>
<caption> </caption>• No dosage adjustment of oral dexamethasone needed</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Methylprednisolone</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>Increased methylprednisolone exposure [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="underline">125-mg/80-mg/80-mg aprepitant regimen</content>
</item>
<item>
<caption> </caption>• Reduce the dose of intravenous methylprednisolone by approximately 25%</item>
<item>
<caption> </caption>• Reduce the dose of oral methylprednisolone by approximately 50% </item>
<item>
<caption> </caption>
<content stylecode="underline">Single 40 mg dose of aprepitant</content>
</item>
<item>
<caption> </caption>• No dosage adjustment of methylprednisolone needed</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Chemotherapeutic agents that are metabolized by CYP3A4</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>Increased exposure of the chemotherapeutic agent may increase the risk of adverse reactions [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="underline">Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents</content>
</item>
<item>
<caption> </caption>• Monitor for chemotherapeutic-related adverse reactions.</item>
<item>
<caption> </caption>
<content stylecode="underline">Etoposide, vinorelbine, paclitaxel, and docetaxel</content>
</item>
<item>
<caption> </caption>• No dosage adjustment needed.</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Hormonal Contraceptives</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Decreased hormonal exposure during administration of and for 28 days after administration of the last dose of aprepitant [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Alternative or back-up methods of contraception should be used during treatment with aprepitant and for 1 month following the last dose of aprepitant</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Examples</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>birth control pills, skin patches, implants, and certain IUDs</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">CYP2C9 Substrates</content>
</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">Warfarin</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Decreased warfarin exposure and prolongation of prothrombin time (INR) [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>In patients on chronic warfarin therapy, monitor the prothrombin time (INR) in the 2-week</item>
<item>
<caption> </caption>period, particularly at 7 to 10 days, following initiation of the 125-mg/80-mg/80-mg aprepitant regimen with each chemotherapy cycle, or following administration of a single 40-mg dose of aprepitant.</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">Other</content>
</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">
<content stylecode="italics">5-HT3 Antagonists</content>
</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>No change in the exposure of the 5-HT3 antagonist [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>No dosage adjustment needed</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Examples</content>
</item>
</list>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>ondansetron, granisetron, dolasetron</item>
</list>
</td>
</tr>
</tbody>
</table>